Aminolevulinic acid
Aminolevulinic acid (Ala), also known as 5-aminolevulinic acid (5-Ala), is a naturally occurring, non-proteinogenic amino acid that serves as the universal precursor to the tetrapyrrole biosynthetic pathway in virtually all living organisms.
Aminolevulinic acid (Ala), also known as 5-aminolevulinic acid (5-Ala), is a naturally occurring, non-proteinogenic amino acid that serves as the universal precursor to the tetrapyrrole biosynthetic pathway in virtually all living organisms. It is synthesized endogenously via either the C4 pathway, from glycine and succinyl-CoA in a reaction catalyzed by Ala synthase, or the C5 pathway, from glutamyl-tRNA, and subsequently undergoes a series of enzymatic transformations that culminate in the formation of heme, chlorophyll, and other biologically essential porphyrins. Within mammalian cells, 5-Ala is preferentially taken up and metabolized in tissues with high metabolic activity — most notably neoplastic cells — where it accumulates as the fluorescent photosensitizer protoporphyrin IX (PpIX). This selective intracellular accumulation underpins 5-Ala's dual utility as both a diagnostic fluorophore and a photodynamic/radiodynamic agent, making it a molecule of considerable pharmacological interest.
As a therapeutic and theranostic agent, 5-Ala exploits the preferential accumulation of PpIX in tumor tissue. Upon activation by light of appropriate wavelength, PpIX generates reactive oxygen species (ROS) that induce localized cytotoxic effects — a process central to photodynamic therapy (PDT). Beyond PDT, 5-Ala's PpIX-mediated fluorescence enables real-time intraoperative tumor visualization. These properties have positioned 5-Ala at the intersection of oncology, photomedicine, and precision surgery, with an expanding evidence base across dermatologic, gynecologic, neurologic, and musculoskeletal malignancies including ovarian cancer and breast cancer.
Where the papers sit
9 papers from the last 6 months study aminolevulinic acid directly · updated from PubMed 28 Oct 2026
Study type 0 clinical trials · 4 observational · 5 preclinical
Themes 3 themes · 1 new direction
-
Photodynamic Therapy in Cancer
Photodynamic therapy is being extended from established lesion treatment toward more selective and less phototoxic approaches. Pt(IV) prodrugs generate protoporphyrin IX in situ, while cathepsin B-activated 5-ALA prodrugs aim to concentrate phototoxicity in tumors. Clinical studies in oral leukoplakia and extramammary Paget disease focus on response, recurrence, and treatment-related factors. The main open issue is translating improved targeting into durable clinical control.
4 papers · 44.4%
-
Fluorescence-Guided Glioblastoma Surgery
Fluorescence-guided resection is being assessed against the limits of contrast enhancement in glioblastoma surgery. 5-ALA and sodium fluorescein are compared for defining resection margins, including FLAIR abnormalities and nonenhancing disease. Extent of resection remains the central endpoint, with survival used to test whether broader fluorescence-defined removal improves outcomes. The evidence supports complementary imaging rather than a settled choice between the two agents.
2 papers · 22.2%
-
Others — 5-ALA Translational Research
Radiodynamic therapy is being explored as a treatment for osteosarcoma, using 5-ALA-derived protoporphyrin IX and irradiation to suppress tumors. In parallel, metabolic engineering of Escherichia coli seeks to increase 5-ALA production. The cluster therefore links therapeutic application with upstream manufacturing rather than a single disease program. Whether radiodynamic efficacy can translate beyond preclinical osteosarcoma models remains open.
3 papers · 33.3%
Engineered Escherichia coli can serve as a high-yield manufacturing platform for 5-ALA
The metabolically engineered Escherichia coli production strain treated 5-ALA not as a tumor-localizing precursor, photosensitizer, imaging agent, or component of a therapeutic construct, but as the product of an industrial biosynthetic process, reaching 55.11 g/L in a 5-L bioreactor 42231739Jun. This gives 5-ALA a distinct role as a manufactured agricultural and pharmaceutical commodity and shifts the focus from using the molecule in biological treatment to producing it at scale.
Papers
The 9 papers from the last 6 months that study aminolevulinic acid directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Photodynamic Therapy in Cancer (4)
- Clinical Efficacy of 5-Aminolevulinic Acid Photodynamic Therapy in the Treatment of Oral Leukoplakia: A Prospective Study with Long-Term Follow-Up. Oral health & preventive dentistry · 29 Sept 2026 PMID 42808717
- Treatment outcomes and influencing factors of photodynamic therapy in extramammary Paget's disease: a retrospective analysis of 31 cases. The Journal of dermatological treatment · 3 Aug 2026 PMID 42545809
- A Pt(IV) prodrug for cancer chemo-photodynamic therapy preventing skin photosensitivity via in situ PpIX generation. Chemical communications (Cambridge, England) · 27 Jul 2026 PMID 42504784
- Dual-masked cathepsin B-activated 5-aminolevulinic acid prodrugs with enhanced photodynamic cytotoxicity. Bioorganic chemistry · 10 Jul 2026 PMID 42430823
Fluorescence-Guided Glioblastoma Surgery (2)
- Impact of 5-ALA and sodium fluorescein on FLAIR volume extent of resection and survival in IDH-wildtype glioblastoma. Journal of neuro-oncology · 16 Sept 2026 PMID 42749959
- Contrast-enhancement-defined resection outcomes with sodium fluorescein and 5-aminolevulinic acid in glioblastoma surgery: a multicenter retrospective cohort of 1389 patients. Journal of neuro-oncology · 26 Aug 2026 PMID 42649357
Others — 5-ALA Translational Research (3)
- Radiodynamic Therapy Using Local Administration of 5-Aminolevulinic Acid for In Vivo Osteosarcoma Xenograft Model. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665407
- Systematic Metabolic Engineering of Escherichia coli for High-Level Production of 5-Aminolevulinic Acid. ACS synthetic biology · 3 Jun 2026 PMID 42231739
- Radiodynamic Therapy Using 5-Aminolevulinic Acid as a New Treatment Option for Osteosarcoma: An In Vitro and In Vivo Study. Anticancer research · 27 May 2026 PMID 42203311
By study type
Observational studies and case reports (4)
- Clinical Efficacy of 5-Aminolevulinic Acid Photodynamic Therapy in the Treatment of Oral Leukoplakia: A Prospective Study with Long-Term Follow-Up. Oral health & preventive dentistry · 29 Sept 2026 PMID 42808717
- Impact of 5-ALA and sodium fluorescein on FLAIR volume extent of resection and survival in IDH-wildtype glioblastoma. Journal of neuro-oncology · 16 Sept 2026 PMID 42749959
- Contrast-enhancement-defined resection outcomes with sodium fluorescein and 5-aminolevulinic acid in glioblastoma surgery: a multicenter retrospective cohort of 1389 patients. Journal of neuro-oncology · 26 Aug 2026 PMID 42649357
- Treatment outcomes and influencing factors of photodynamic therapy in extramammary Paget's disease: a retrospective analysis of 31 cases. The Journal of dermatological treatment · 3 Aug 2026 PMID 42545809
Preclinical: animal, cell and lab studies (5)
- Radiodynamic Therapy Using Local Administration of 5-Aminolevulinic Acid for In Vivo Osteosarcoma Xenograft Model. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665407
- A Pt(IV) prodrug for cancer chemo-photodynamic therapy preventing skin photosensitivity via in situ PpIX generation. Chemical communications (Cambridge, England) · 27 Jul 2026 PMID 42504784
- Dual-masked cathepsin B-activated 5-aminolevulinic acid prodrugs with enhanced photodynamic cytotoxicity. Bioorganic chemistry · 10 Jul 2026 PMID 42430823
- Systematic Metabolic Engineering of Escherichia coli for High-Level Production of 5-Aminolevulinic Acid. ACS synthetic biology · 3 Jun 2026 PMID 42231739
- Radiodynamic Therapy Using 5-Aminolevulinic Acid as a New Treatment Option for Osteosarcoma: An In Vitro and In Vivo Study. Anticancer research · 27 May 2026 PMID 42203311
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-18 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.